Market Pulse

  • Most Popular
  • Most Shared

REUTERS SHOWCASE

Tracking Sensex

Tracking Sensex

Top five losers, gainers this week.  Full Article 

AirAsia  in India

AirAsia in India

AirAsia India launch seen in Q4; may order 50 more Airbus jets: CEO.  Full Article 

Jet-Etihad Deal

Jet-Etihad Deal

Jet Airways shareholders approve Etihad deal.  Full Article 

Tata Steel Shines

Tata Steel Shines

Tata Steel surges; Q4 operating profit beats f'cast.  Full Article 

RBI's May Review

RBI's May Review

Subbarao overrules panel view on rate action in May.  Full Article 

Abe's Agenda

Abe's Agenda

Special Report - The deeper agenda behind "Abenomics".  Full Article 

Bernanke Impact

Bernanke Impact

U.S. Fed enters delicate new phase of communication  Full Article | Related Story 

Revenge of Markets

Revenge of Markets

For months, markets have been dancing to central bankers' tune, but that may now be changing, writes James Saft.  Full Article 

Buy, Sell or Hold?

Buy, Sell or Hold?

Confused while buying stocks? Get buy, sell or hold recommendations from VantageTrade.  Full Coverage 

Reuters India Mobile

Reuters India Mobile

Get the latest news on the go. Visit Reuters India on your mobile device.  Full Coverage 

Claris in JV with Japan's Otsuka Pharma, Mitsui for drugs biz

Related Topics

Stocks

   
Track BSE Sectoral Indices

Track Markets: BSE Sectoral Indices

Track and analyse performance of all BSE sectoral indices and other global indices on a single page.   Full Coverage 

MUMBAI | Fri Dec 7, 2012 1:22pm IST

MUMBAI (Reuters) - Drugmaker Claris Lifesciences Ltd (CLAI.BO) said on Friday it will form a joint venture with Japan's Otsuka Pharmaceutical Factory and Mitsui & Co Ltd (8031.T) for its medical infusion drugs business in India and emerging countries.

Claris said its board also approved the sale of its infusion business, on a slump basis, to the company's fully-owned unit, Claris Speciality Injectables, which will eventually run the joint venture.

(Reporting by Kaustubh Kulkarni in MUMBAI)

Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.